NCT01528163View on ClinicalTrials.gov

Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Cabazitaxel

from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.

DRUG

Methotrexate

From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.

Trial Locations (16)

1090

Universitair Ziekenhuis Brussel (Campus Jette), Brussels

1200

Cliniques universitaires Saint-Luc, Centre du Cancer, Oncologie Médicale, Brussels

1340

Clinique Saint-Pierre, Ottignies

4000

CHR Citadelle, Liège

CHU de Liège Sart Tilman, Liège

5000

Clinique et Maternité Sainte-Elisabeth, Namur

5530

CHU de Mont Godinne, Yvoir

6000

Grand Hôpital de Charleroi, Charleroi

6110

CHU de Charleroi site Vésale, Montigny-le-Tilleul

7000

CHU Ambroise PARE, Mons

7100

Hôpital de Jolimont, Haine-Saint-Paul

CHU Tivoli Centre René Goffin, La Louvière

7331

RHMS Baudour, Baudour

7500

Centre Hospitalier Wallonie Picarde, Tournai

9000

Universitair Ziekenhuis Gent, Ghent

L-1210

Centre Hospitalier de Luxembourg, Luxembourg

All Listed Sponsors
lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

NCT01528163 - Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter